Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe

Balgobind, Sapna; Cheung, Veronica K.Y.; Luk, Peter; Low, Tsu-Hui Hubert; Wykes, James; Wu, Raymond; Lee, Jenny; Ch'ng, Sydney; Palme, Carsten E.; Clark, Jonathan R.; Gupta, Ruta

doi:10.1016/j.pathol.2023.11.005

Cited by 2 publications

(3 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the identification of factors holding prognostic or predictive significance is of critical importance in guiding patient management. Patients with unfavorable prognostic factors may require more aggressive treatment, and patients with predictive biological markers may benefit from specific therapeutic strategies [78]. Traditionally recognized prognostic and/or predictive factors include tumor site and size, tumor grade and differentiation, depth of invasion, lympho-vascular and perineural invasion, and LN metastases [78].…”

Section: Prognostic Significance Of Pre-treatment Pet/ctmentioning

confidence: 99%

“…Patients with unfavorable prognostic factors may require more aggressive treatment, and patients with predictive biological markers may benefit from specific therapeutic strategies [78]. Traditionally recognized prognostic and/or predictive factors include tumor site and size, tumor grade and differentiation, depth of invasion, lympho-vascular and perineural invasion, and LN metastases [78]. More recently, biological markers, such as HPV detection in oropharyngeal SCC and Epstein-Barr virus detection in nasopharyngeal carcinomas, as well as specific genetic changes, have been applied (see below Section 3.6) [78].…”

Section: Prognostic Significance Of Pre-treatment Pet/ctmentioning

confidence: 99%

“…Traditionally recognized prognostic and/or predictive factors include tumor site and size, tumor grade and differentiation, depth of invasion, lympho-vascular and perineural invasion, and LN metastases [78]. More recently, biological markers, such as HPV detection in oropharyngeal SCC and Epstein-Barr virus detection in nasopharyngeal carcinomas, as well as specific genetic changes, have been applied (see below Section 3.6) [78]. In this context, the prognostic and predictive value of various 18 F-FDG pre-treatment parameters in patients with HNSCC has been extensively investigated.…”

Section: Prognostic Significance Of Pre-treatment Pet/ctmentioning

confidence: 99%

See 2 more Smart Citations

Role of 18F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications

Caldarella,

De Risi,

Massaccesi

et al. 2024

Cancers

View full text Add to dashboard Cite

This article provides an overview of the use of 18F-FDG PET/CT in various clinical scenarios of head–neck squamous cell carcinoma, ranging from initial staging to treatment-response assessment, and post-therapy follow-up, with a focus on the current evidence, debated issues, and innovative applications. Methodological aspects and the most frequent pitfalls in head–neck imaging interpretation are described. In the initial work-up, 18F-FDG PET/CT is recommended in patients with metastatic cervical lymphadenectomy and occult primary tumor; moreover, it is a well-established imaging tool for detecting cervical nodal involvement, distant metastases, and synchronous primary tumors. Various 18F-FDG pre-treatment parameters show prognostic value in terms of disease progression and overall survival. In this scenario, an emerging role is played by radiomics and machine learning. For radiation-treatment planning, 18F-FDG PET/CT provides an accurate delineation of target volumes and treatment adaptation. Due to its high negative predictive value, 18F-FDG PET/CT, performed at least 12 weeks after the completion of chemoradiotherapy, can prevent unnecessary neck dissections. In addition to radiomics and machine learning, emerging applications include PET/MRI, which combines the high soft-tissue contrast of MRI with the metabolic information of PET, and the use of PET radiopharmaceuticals other than 18F-FDG, which can answer specific clinical needs.

show abstract

Section: Prognostic Significance Of Pre-treatment Pet/ctmentioning

confidence: 99%